Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P070 - Pembrolizumab for Non-Small Cell Lung Cancer with Untreated Central Nervous System Metastases: A Case Report (ID 101)
00:00 - 00:00 | Author(s): M. Di
Non?small cell lung cancer (NSCLC) accounts for up to 85% of lung cancers. Central nervous system(CNS) metastasis is a common complication of NSCLC with a poor prognosis and dismal survival rate. Treatment is limited and has poor outcomes and affects the quality of the life of patients. Pembrolizumab is a Programmed cell death-1 (PD-1) antibody, has shown good results in management of NSCLC. However, it has not been well studied for CNS penetration, and patients with untreated brain metastases are excluded from most clinical trials.
We hereby report 2 cases of NSCLC patients with brain metastases who successfully treated with pembrolizumab, to discuss the efficacy and safety of pembrolizumab in NSCLC patients with brain metastases.
In the present cases, patients with untreated/progressing brain metastases can be well controlled with pembrolizumab and have a long PFS with a high quality of life by using pembrolizumab. Neither of the patients have treatment-related serious and grade 3